BIOMAT Database Logo BIOMAT Database Logo

Activation by synthetic lipid A subunit analogues (GLA compounds) of tumoricidal properties in human blood monocytes. 1990

H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.

The authors have determined that synthetic lipid A subunit analogues (GLA compounds), as well as E. coli type lipopolysaccharide (LPS) and synthetic lipid A (compound 506), are able to stimulate human monocytes to become cytotoxic against tumour target cells in vitro. GLA-60, a synthetic lipid A subunit analogue of low toxicity, was found to be more active for the induction of tumoricidal monocytes than GLA-59, and similar to that of LPS. GLA-60 could induce not only the secretion of cytotoxic factor into the culture supernatant but also expression of the membrane-associated form of cytotoxic factor in human monocytes. Supernatant-mediated cytotoxicity was completely inhibited by the addition of monoclonal anti-human TNF antibody. These results indicate that a synthetic lipid A subunit analogue, GLA-60, would be a useful activator of tumoricidal monocytes in spite of its low toxicity.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008050 Lipid A Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
May 1983, Cancer research,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.
March 1986, Journal of immunology (Baltimore, Md. : 1950),
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Activation of cytokine production, tumoricidal properties, and tyrosine phosphorylation of MAPKs in human monocytes by a new synthetic lipopeptide, JBT3002.
June 1998, Journal of leukocyte biology,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma.
February 1986, Cancer research,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Suppression by interleukin 4 of activation of human blood monocytes to the tumoricidal state.
September 1990, Japanese journal of cancer research : Gann,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.
January 1991, Cancer immunology, immunotherapy : CII,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Antiviral and immunomodulating activities of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-60.
January 1988, Antiviral research,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon.
January 1985, Cancer immunology, immunotherapy : CII,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Intracellular activation of tumoricidal properties in mouse macrophages and human monocytes by recombinant mouse or human gamma interferon encapsulated in liposomes.
January 1986, Annales de l'Institut Pasteur. Immunologie,
H Maeda, and I Saiki, and N Yamamoto, and T Takahashi, and S Sekiguchi, and M Kiso, and A Hasegawa, and I Azuma
Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GLA-60.
January 1991, International journal of immunopharmacology,
Copied contents to your clipboard!